Concepedia

Publication | Open Access

Cost-effectiveness of empagliflozin in patients with type 2 diabetes and established cardiovascular disease in China

DOIFull Paper Access

12

Citations

29

References

2021

Year

Mafalda Ramos, Peng Men, Xu Wang, Anastasia Ustyugova, Mark Lamotte
Cost Effectiveness and Resource Allocation

Abstract

Results suggest that empagliflozin + SoC is cost-effective compared to sitagliptin + SoC and liraglutide + SoC at a willingness-to-pay threshold of 212,676RMB ($30,292)/QALY.

References

YearCitations

Page 1